MKC8866
规格
| Cas Number | 1338934-59-0 |
| 规格或纯度 | ≥97% |
| 纯度 | ≥97% |
| 包装 | 100mg 或 250mg 或 50mg 或 5mg 或 25mg 或 2mg |
产品信息
| 别名 | 7-羟基-6-甲氧基-4-甲基-3-(2-吗啉-2-氧乙基)-2-氧代-2H-苯并吡喃-8-醛 |
| 品牌 | 阿拉丁 |
| 溶解性 | Solubility (25°C) In vitro DMSO: 3 mg/mL (8.3 mM); Water: ˂1 mg/mL Ethanol: ˂1 mg/mL |
| 简短描述 | IRE1 抑制剂 |
| 英文简短描述 | IRE1 Inhibitors |
| 过滤标签 | IRE1,Cell Cycle/DNA Damage |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | MKC8866（IRE1-IN-8866）是一种水杨醛类似物，是一种特异性 IRE1α RNase 抑制剂，在体外对人类 IRE1α 的 IC50 为 0.29u2009μM 。 |
| 英文描述 |
Information MKC8866 MKC8866 (IRE1-IN-8866), a salicylaldehyde analog, is a specific IRE1α RNase inhibitor with IC50 of 0.29 μM for human IRE1α in vitro. Targets hIRE1α (Cell-free assay) 0.29 μM In vitro MKC8866 is optimized and refined from a family of IRE1α-specific endoribonuclease inhibitors obtained from a chemical library screen. MKC8866 effectively represses IRE1α-mediated XBP1 splicing in PCa cells and has favorable pharmacokinetic and pharmacodynamic properties. In vivo MKC8866 is an IRE1α RNase-specific inhibitor molecule that displays significant therapeutic activity in various preclinical models of PCa in vivo. MKC8866 synergizes with clinical PCa drugs in vivo. Cell Research(from reference) Cell lines：human PCa cell lines LNCaP and 22Rv1, VCaP cell line, C4-2B cell line Concentrations：0.2-10 μM Incubation Time：0.25-24 h |